Is GE Healthcare Technologies, Inc. overvalued or undervalued?

As of 14 November 2025, the valuation grade for GE Healthcare Technologies, Inc. has moved from very attractive to attractive, indicating a shift towards a more cautious outlook. The company appears to be overvalued given its current metrics, particularly when compared to its peers. The P/E ratio stands at 14, while the PEG ratio is notably low at 0.39, suggesting that the stock is priced attractively relative to its growth potential, but this is offset by a relatively high Price to Book Value of 3.57.
In comparison to peers, GE Healthcare's P/E ratio of 14 is significantly lower than that of Edwards Lifesciences Corp. at 31.17 and Agilent Technologies, Inc. at 27.42, indicating that it may be undervalued relative to these companies. However, the overall market performance shows that GE Healthcare has underperformed the S&P 500 year-to-date with a return of -6.43% compared to the index's 14.49%, reinforcing the notion that the stock may be overvalued in the current market environment.